|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9511220D0
(en)
*
|
1995-06-02 |
1995-07-26 |
Glaxo Group Ltd |
Solid dispersions
|
|
US6046216A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
|
US5874440A
(en)
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
|
US6060477A
(en)
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
|
GB9514473D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
EP0912567B1
(en)
*
|
1996-05-10 |
2002-04-10 |
Icos Corporation |
Carboline derivatives
|
|
US6331543B1
(en)
*
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US6071934A
(en)
|
1997-03-25 |
2000-06-06 |
Cell Pathways, Inc. |
Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
|
|
JP2002505676A
(ja)
|
1997-06-23 |
2002-02-19 |
クイーンズ ユニバーシティー アット キングストン |
微量投与療法
|
|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
|
IL132406A0
(en)
*
|
1998-10-21 |
2001-03-19 |
Pfizer Prod Inc |
Treatment of bph with cgmp elevators
|
|
US6133271A
(en)
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6211220B1
(en)
|
1998-11-23 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
US6420410B1
(en)
|
1998-11-24 |
2002-07-16 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
US6358992B1
(en)
|
1998-11-25 |
2002-03-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with indole derivatives
|
|
EP1162970B1
(en)
|
1999-03-24 |
2003-12-17 |
Harbor Branch Oceanographic Institution, Inc. |
Anti-inflammatory uses of manzamines
|
|
ES2187234A1
(es)
*
|
1999-04-30 |
2003-05-16 |
Lilly Icos Llc |
Forma de dosificacion oral para tratar la disfuncion sexual.
|
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
US6943166B1
(en)
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
MXPA02001196A
(es)
*
|
1999-08-03 |
2003-02-12 |
Lilly Icos Llc |
Composiciones farmaceuticas de °-carbolina.
|
|
US6821975B1
(en)
|
1999-08-03 |
2004-11-23 |
Lilly Icos Llc |
Beta-carboline drug products
|
|
CZ20021151A3
(cs)
|
1999-10-11 |
2003-03-12 |
Pfizer Inc. |
5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
|
|
TW200400821A
(en)
*
|
1999-11-02 |
2004-01-16 |
Pfizer |
Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
|
|
US6562830B1
(en)
|
1999-11-09 |
2003-05-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
|
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
CA2407031A1
(en)
|
2000-04-19 |
2001-10-25 |
Lilly Icos Llc |
Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
|
|
UA74826C2
(en)
*
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
WO2001094345A2
(en)
|
2000-06-07 |
2001-12-13 |
Lilly Icos Llc |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
|
WO2002000658A1
(en)
*
|
2000-06-23 |
2002-01-03 |
Lilly Icos Llc |
Cyclic gmp-specific phosphodiesterase inhibitors
|
|
DE60121048T2
(de)
|
2000-06-23 |
2007-01-25 |
Lilly Icos Llc, Wilmington |
PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
|
|
WO2002000657A2
(en)
*
|
2000-06-26 |
2002-01-03 |
Lilly Icos Llc |
Condensed pyrazindione derivatives
|
|
MXPA03000688A
(es)
*
|
2000-07-24 |
2004-11-01 |
Bayer Cropscience Ag |
Bifenilcarboxiamidas.
|
|
MXPA03000887A
(es)
*
|
2000-08-02 |
2004-04-05 |
Lilly Icos Llc |
Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
|
|
US6503894B1
(en)
*
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
DE60111553T2
(de)
*
|
2000-10-02 |
2006-04-06 |
Lilly Icos Llc, Wilmington |
Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
|
|
EP1335917B1
(en)
|
2000-10-02 |
2005-08-24 |
Lilly Icos LLC |
Condensed pyridoindole derivatives
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
EP1211313A3
(en)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation of PDE11A activity
|
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
|
AU2002211493A1
(en)
|
2000-11-06 |
2002-05-15 |
Lilly Icos Llc |
Indole derivatives as pde5-inhibitors
|
|
CA2441792C
(en)
*
|
2001-04-25 |
2010-08-03 |
Lilly Icos Llc |
Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
|
|
FR2824829B1
(fr)
*
|
2001-05-16 |
2005-06-03 |
Macef |
Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
|
|
ATE397606T1
(de)
|
2001-06-05 |
2008-06-15 |
Lilly Icos Llc |
Pyrazino(1',2':1,6)-pyrido(3,4-b) indole-1,4- dionderivate
|
|
ES2286291T3
(es)
*
|
2001-06-05 |
2007-12-01 |
Lilly Icos Llc |
Compustos tetraciclicos como inhibidores de pde5.
|
|
EP1401835A1
(en)
*
|
2001-06-05 |
2004-03-31 |
Lilly Icos LLC |
Carboline derivatives as pde-5 inhibitors
|
|
EP1397361B1
(en)
|
2001-06-21 |
2006-08-09 |
Lilly Icos LLC |
Carboline derivatives as pdev inhibitors
|
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
|
CA2465893A1
(en)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
|
EP1448562B1
(en)
*
|
2001-11-14 |
2007-07-25 |
Ortho-Mcneil Pharmaceutical Corp. |
Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
BR0311191A
(pt)
*
|
2002-05-23 |
2005-03-01 |
Pfizer |
Combinação
|
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
|
ATE415402T1
(de)
*
|
2002-07-31 |
2008-12-15 |
Lilly Icos Llc |
Modifizierte pictet-spengler-reaktion und damit hergestellte verbindungen
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
PT1572173E
(pt)
|
2002-12-13 |
2010-05-10 |
Warner Lambert Co |
Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
|
|
AU2004226353A1
(en)
|
2003-04-01 |
2004-10-14 |
Laboratoires Serono Sa |
Inhibitors of phosphodiesterases in infertility
|
|
KR100824193B1
(ko)
|
2003-04-29 |
2008-04-21 |
화이자 인코포레이티드 |
고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
|
|
NZ544040A
(en)
*
|
2003-05-22 |
2009-03-31 |
Nycomed Gmbh |
Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
|
|
PL1644021T3
(pl)
*
|
2003-06-13 |
2013-01-31 |
Ironwood Pharmaceuticals Inc |
Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
|
|
JP4671123B2
(ja)
*
|
2003-06-23 |
2011-04-13 |
小野薬品工業株式会社 |
新規三環性複素環化合物
|
|
US7291640B2
(en)
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
EP1699436A2
(en)
*
|
2003-12-12 |
2006-09-13 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
|
US7449462B2
(en)
|
2004-01-22 |
2008-11-11 |
Pfizer, Inc. |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
|
JP2007530566A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
JP2007530563A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
BRPI0509731A
(pt)
|
2004-04-07 |
2007-09-25 |
Pfizer |
pirazol[4,3-d]pirimidinas
|
|
WO2005116030A1
(en)
*
|
2004-05-31 |
2005-12-08 |
Matrix Laboratories Ltd |
A process for the preparation of tadalafil
|
|
EP1776108A1
(en)
*
|
2004-06-23 |
2007-04-25 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
JP5070052B2
(ja)
|
2004-08-17 |
2012-11-07 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
Ｐｄｅ５阻害剤組成物及び心臓疾患を治療する方法
|
|
EP1804582A4
(en)
*
|
2004-10-28 |
2009-12-09 |
Reddys Lab Ltd Dr |
POLYMORPH SHAPES OF TADALAFIL
|
|
CA2582092A1
(en)
*
|
2004-11-02 |
2006-05-11 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil crystal forms and processes for preparing them
|
|
AR051780A1
(es)
*
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
ES2459742T3
(es)
|
2004-12-22 |
2014-05-12 |
Ono Pharmaceutical Co., Ltd. |
Compuesto tricíclico y uso del mismo
|
|
US20070004737A1
(en)
*
|
2005-02-25 |
2007-01-04 |
Inbal Ornan |
Process of purifying tadalafil
|
|
US7417044B2
(en)
*
|
2005-02-25 |
2008-08-26 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil having a large particle size and a process for preparation thereof
|
|
MX2007009707A
(es)
*
|
2005-02-25 |
2007-09-12 |
Teva Pharma |
Proceso para sintetizar tadalafil.
|
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
|
KR20070110941A
(ko)
*
|
2005-04-12 |
2007-11-20 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타달라필 중간체의 제조 방법
|
|
KR101358479B1
(ko)
|
2005-04-19 |
2014-02-06 |
다케다 게엠베하 |
폐고혈압 치료용 로플루밀라스트
|
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
|
PL1881985T3
(pl)
|
2005-05-12 |
2011-05-31 |
Pfizer |
Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu
|
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
|
KR20080047375A
(ko)
|
2005-07-29 |
2008-05-28 |
콘서트 파마슈티컬즈, 인크. |
약제 화합물
|
|
US7863274B2
(en)
*
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
|
WO2007014929A1
(en)
|
2005-08-03 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Use of flibanserin in the treatment of obesity
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
US20070104792A1
(en)
*
|
2005-09-13 |
2007-05-10 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
|
PL2450041T3
(pl)
|
2005-10-12 |
2019-02-28 |
Unimed Pharmaceuticals, Llc |
Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu
|
|
AU2006304787A1
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
JP2009513604A
(ja)
|
2005-10-29 |
2009-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
|
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
WO2007100387A2
(en)
*
|
2005-11-03 |
2007-09-07 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing tadalafil
|
|
TWI435729B
(zh)
|
2005-11-09 |
2014-05-01 |
Combinatorx Inc |
治療病症之方法，組合物及套組
|
|
US7201929B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
US7202229B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
CA2643199A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
WO2007110734A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of tadalafil
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
AU2007249435A1
(en)
*
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
US20090291958A1
(en)
*
|
2006-06-08 |
2009-11-26 |
Auspex Pharmaceuticals, Inc. |
Substituted PDE5 inhibitors
|
|
US20090312242A1
(en)
|
2006-06-30 |
2009-12-17 |
Ramiro Castro |
Flibanserin for the treatment of urinary incontinence and related diseases
|
|
US20080009502A1
(en)
*
|
2006-07-07 |
2008-01-10 |
Access Business Group International Llc |
Tadalafil solid composites
|
|
CN101516335B
(zh)
|
2006-07-21 |
2014-01-08 |
诺瓦提斯公司 |
苯并咪唑基吡啶基醚的制剂
|
|
AU2007286288A1
(en)
|
2006-08-14 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Formulations of flibanserin and method for manufacturing the same
|
|
CN101505736A
(zh)
|
2006-08-25 |
2009-08-12 |
贝林格尔.英格海姆国际有限公司 |
控制释放系统及其制造方法
|
|
AR062501A1
(es)
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
|
BRPI0716604A2
(pt)
*
|
2006-09-08 |
2013-04-09 |
Braincells Inc |
combinaÇÕes contendo um derivado de 4-acilaminopiridina
|
|
EP2066355A2
(en)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2952193A1
(en)
|
2006-12-12 |
2015-12-09 |
Gilead Sciences, Inc. |
Composition for treating a pulmonary hypertension
|
|
WO2008095136A2
(en)
|
2007-01-31 |
2008-08-07 |
Henkin Robert I |
Methods for detection of biological substances
|
|
US20080261991A1
(en)
|
2007-02-12 |
2008-10-23 |
Dmi Biosciences, Inc. |
Reducing Side Effects of Tramadol
|
|
DK2120570T3
(da)
|
2007-02-12 |
2012-06-25 |
Dmi Biosciences Inc |
Behandling af præmatur komorbid ejakulation og erektil dysfunktion
|
|
WO2008103470A2
(en)
*
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
AU2008245597A1
(en)
*
|
2007-04-25 |
2008-11-06 |
Teva Pharmaceutical Industries Ltd. |
Solid dosage forms
|
|
FR2916200A1
(fr)
*
|
2007-05-18 |
2008-11-21 |
Fourtillan Snc |
Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
|
|
DE102007028869A1
(de)
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
HRP20120686T1
(hr)
|
2007-06-29 |
2012-09-30 |
Ranbaxy Laboratories Limited |
Postupak priprave intermedijera tricikličkih spojeva
|
|
EP2033962A1
(en)
*
|
2007-08-22 |
2009-03-11 |
4Sc Ag |
Tetracyclic indolopyridines as EG5 inhibitors
|
|
CL2008002693A1
(es)
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
|
US20090181975A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
ITMI20080285A1
(it)
*
|
2008-02-22 |
2009-08-23 |
Endura Spa |
Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
|
|
EP2107059A1
(en)
*
|
2008-03-31 |
2009-10-07 |
LEK Pharmaceuticals D.D. |
Conversion of tryptophan into ß-carboline derivatives
|
|
PL385356A1
(pl)
|
2008-06-03 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania tadalafilu
|
|
US8580801B2
(en)
*
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
EP2181997A1
(en)
|
2008-10-30 |
2010-05-05 |
Chemo Ibérica, S.A. |
A process for the preparation of tadalafil
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
JP2012513464A
(ja)
|
2008-12-23 |
2012-06-14 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
ホスホジエステラーゼ阻害剤及びその使用
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
EP2400848A4
(en)
|
2009-02-26 |
2012-07-25 |
Thar Pharmaceuticals Inc |
CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
|
EP2556820A4
(en)
|
2010-04-05 |
2015-01-21 |
Sk Chemicals Co Ltd |
COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
US20120269898A1
(en)
|
2010-10-15 |
2012-10-25 |
Luiz Belardinelli |
Compositions and methods of treating pulmonary hypertension
|
|
EP2673275B1
(en)
|
2011-02-10 |
2015-04-08 |
Interquim, S.A. |
Process for obtaining compounds derived from tetrahydro-beta-carboline
|
|
WO2012107541A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
|
WO2012107090A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Granulated composition comprising tadalafil and a disintegrant
|
|
WO2012107092A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
|
US20120123124A1
(en)
*
|
2011-04-22 |
2012-05-17 |
Drug Process Licensing Associates, LLC |
Manufacturing process for Tadalafil from racemic or L-tryptophan
|
|
CN102180876B
(zh)
*
|
2011-05-28 |
2016-05-18 |
浙江华海药业股份有限公司 |
一种他达那非晶型i的制备方法
|
|
EP2535049A1
(en)
|
2011-06-17 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Tadalafil for the treatment of dementia
|
|
CN102367253B
(zh)
*
|
2011-09-20 |
2016-04-06 |
浙江华海药业股份有限公司 |
一种制备他达拉非晶型a的方法
|
|
WO2013067309A1
(en)
|
2011-11-04 |
2013-05-10 |
Xion Pharmaceutical Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
WO2013109227A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical compositions comprising ceftibuten
|
|
WO2013109223A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
WO2013109230A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical compositions comprising tadalafil
|
|
WO2013129889A2
(ko)
|
2012-02-28 |
2013-09-06 |
주식회사 서울제약 |
실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
|
|
EP2903619B1
(en)
|
2012-10-05 |
2019-06-05 |
Robert I. Henkin |
Phosphodiesterase inhibitors for treating taste and smell disorders
|
|
EP3981409A1
(en)
|
2012-12-04 |
2022-04-13 |
Aribio Inc. |
Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
WO2014100733A1
(en)
|
2012-12-21 |
2014-06-26 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating calcific aortic valve stenosis
|
|
KR20150119871A
(ko)
|
2013-02-21 |
2015-10-26 |
아드베리오 파마 게엠베하 |
메틸 ｛4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리디노-3-일]피리미디노-5-일｝메틸 카르바메이트의 형태
|
|
CN103232451A
(zh)
*
|
2013-05-14 |
2013-08-07 |
张家港威胜生物医药有限公司 |
一种他达那非的简易制备工艺
|
|
ES2776353T3
(es)
|
2013-07-17 |
2020-07-30 |
Univ Columbia |
Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
|
|
US20160317542A1
(en)
|
2013-12-09 |
2016-11-03 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
|
EP3108245B1
(en)
|
2014-02-18 |
2020-07-22 |
Robert I. Henkin |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
|
AR099416A1
(es)
|
2014-02-28 |
2016-07-20 |
Lilly Co Eli |
Terapia combinada para la hipertensión resistente
|
|
ES2749433T3
(es)
|
2014-06-23 |
2020-03-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
|
|
ES2784251T3
(es)
|
2014-06-30 |
2020-09-23 |
Montero Gida Sanayi Ve Ticaret As |
Formulaciones de disgregación por vía oral de tadalafilo
|
|
EP2962684A1
(en)
|
2014-06-30 |
2016-01-06 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally disintegrating formulations of tadalafil
|
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
|
WO2016012539A1
(en)
|
2014-07-23 |
2016-01-28 |
Krka, D.D., Novo Mesto |
A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
KR102457316B1
(ko)
|
2015-06-26 |
2022-10-20 |
총킹 디캉 에릴 파마 씨오. 엘티디. |
새로운 5형포스포디에스테라아제 억제제 및 그 용도
|
|
CN105541835B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
|
|
CN105541840B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
关键中间体及其合成方法和在制备他达拉非方面的应用
|
|
CN110381951A
(zh)
|
2016-12-14 |
2019-10-25 |
瑞必治公司 |
用于治疗肺性高血压和其他肺病症的方法及组合物
|
|
CN106977516B
(zh)
*
|
2017-03-02 |
2019-06-18 |
山东裕欣药业有限公司 |
一种他达拉非的制备方法
|
|
EP3952992A4
(en)
|
2019-04-10 |
2023-04-19 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR GENDER-BASED TREATMENT OF CARDIOVASCULAR DYSFUNCTION
|
|
RU2692764C1
(ru)
|
2019-04-26 |
2019-06-27 |
Общество с ограниченной ответственностью "Балтфарма" |
Способ получения тадалафила
|
|
CN111995658B
(zh)
*
|
2019-05-27 |
2022-08-02 |
首都医科大学 |
Ldv修饰的五环哌嗪二酮及其制备和应用
|
|
KR20220035048A
(ko)
|
2019-07-15 |
2022-03-21 |
바이오랩 세너스 팔마씨우티카 엘티디에이. |
화합물 3-(벤조[d][1,3]디옥솔-5-일)-7-(1-하이드록시프로판-2-일)-1-(1H-인돌-3-일)-6,7-디하이드로-3H-옥사졸[3,4-a]피라진-5,8-디온의 입체이성질체 및 항종양제 및 포스포디에스테라제 효소 억제제로서의 이의 용도
|
|
CN110606847A
(zh)
*
|
2019-07-30 |
2019-12-24 |
中国医药集团总公司四川抗菌素工业研究所 |
一种他达拉非顺式中间体的制备方法及其应用
|
|
US11590209B2
(en)
|
2020-01-21 |
2023-02-28 |
Palatin Technologies, Inc. |
Use of bremelanotide in patients with controlled hypertension
|
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|
|
CN120641103A
(zh)
|
2023-01-25 |
2025-09-12 |
阿丽派欧株式会社 |
包含5型磷酸二酯酶抑制剂作为有效成分用于预防或治疗创伤后应激障碍的组合物
|
|
WO2024173675A1
(en)
|
2023-02-16 |
2024-08-22 |
University Of Rochester |
Improving glymphatic-lymphatic efflux
|
|
CN116715667A
(zh)
*
|
2023-06-20 |
2023-09-08 |
常州制药厂有限公司 |
一种他达拉非新晶型b及其制备方法
|